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PEETING HIGHLIGHTS
ighlights of Heart Rhythm 2004, the Annual
cientific Sessions of the Heart Rhythm Society:
ay 19 to 22, 2004, in San Francisco, California
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Heart Rhythm 2004, the 25th Annual Scientific Sessions of the Heart Rhythm Society
(formerly the North American Society of Pacing and Electrophysiology), met in San
Francisco in May 2004. The meeting is the world’s premier forum for the presentation of
research and the exchange of state-of-the-art information in cardiac electrophysiology and
pacing. Major new research findings were presented on the value of implantable cardioverter-
defibrillator therapy, noninvasive methods for risk stratification, treatment of vasovagal
syncope, radiofrequency ablation for atrial fibrillation, resynchronization therapy for heart
failure, and new insights from basic science into the mechanisms of cardiac arrhythmias. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.039Coll Cardiol 2004;44:1550–6) © 2004 by the American College of Cardiology Foundation
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seart Rhythm 2004, the 25th Annual Scientific Sessions of
he newly renamed Heart Rhythm Society (formerly the
orth American Society of Pacing and Electrophysiology),
rew 7,586 registrants (and a total of nearly 11,700 attend-
es) to auditoriums, lecture rooms, and exhibit halls of the
iant Moscone Center in San Francisco, California, repre-
enting a registration increase of approximately 25% over
ast year’s meeting. The meeting is the world’s premier
orum for the release of findings and the exchange of
tate-of-the-art information in cardiac electrophysiology
nd pacing. This year, 906 original scientific reports were
elected from 2,519 submitted abstracts for presentation at
he oral and poster sessions of the four-day meeting. These
eports yielded important news for arrhythmia and pacing
pecialists as well as general cardiologists. Among the major
tories were:
The implantable cardioverter-defibrillator (ICD) was
found to reduce all-cause mortality for patients with
nonischemic dilated cardiomyopathy (DCM) in one trial
but, in another, yielded little benefit if implanted early
after a large myocardial infarction (MI).
From the *Division of Cardiovascular Medicine, University of Florida, Gainesville,
lorida; †Division of Cardiovascular Medicine, The Ohio State University, Colum-
us, Ohio; ‡Cedars-Sinai Medical Center, Los Angeles, California; §Department of
edicine, Medical College of Virginia, Richmond, Virginia; Division of Cardiovas-
ular Diseases, The University of Alabama at Birmingham, Birmingham, Alabama;
Division of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; #Divi-
ion of Cardiology, J.W. Goethe University, Frankfurt, Germany; **Division of
ediatric Cardiology, Duke University Medical Center, Durham, North Carolina;
nd the ††Cardiovascular Division, Brigham and Women’s Hospital, Boston,a
assachusetts.
Manuscript received July 6, 2004, accepted July 13, 2004.An antiarrhythmic agent that was used as an adjunct to
the ICD may be more suited to this role than is the
standard agent amiodarone.
The presence or absence of T-wave alternans (TWA)
may be as useful as QRS duration (QRSd) for refining
risk stratification of patients at already known high risk
of death due to ventricular arrhythmias.
A beta-blocker has been judged the first proven agent for
prevention of vasovagal syncope, although only for a
specific age group.
A verdict delivered by a randomized trial may do much
to settle the debate over the optimal method of abolish-
ing atrial fibrillation (AF) by catheter-based ablation of
cardiac tissue.
Biventricular pacing for cardiac resynchronization ther-
apy (CRT) in patients with heart failure was the meet-
ing’s most prominent theme, and relevant preliminary
reports pointed to a broadening of candidacy for the
treatment.
The following is a brief summary of the meeting
ighlights.
ONINVASIVE EVALUATION
growing trend in the noninvasive evaluation of arrhyth-
ic risk is further stratification of patients at known high
isk of arrhythmic death, including those with impaired left
entricular (LV) function. One potential benefit is more
ost-effective selection of candidates for the ICD. Several
eeting reports pointed to a major role for TWA testing in
uch risk refinement, perhaps an even larger role than is
ccorded to analysis of the QRSd.
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October 19, 2004:1550–6 Highlights of Heart Rhythm 2004Currently, the Centers for Medicare and Medicaid use
he QRSd in deciding whether to reimburse for ICD use in
atients without traditional indications for implantation,
uch as documentation of inducible or spontaneous malig-
ant ventricular arrhythmias. Reimbursement is reserved for
atients with a QRSd 120 ms and additional risk factors
hat include a history of MI and a left ventricular ejection
raction (LVEF) 30%, based on the results of the Multi-
enter Automatic Defibrillator Implantation Trial (MA-
IT) II study. At the San Francisco meeting, Bloomfield et
l. (1) reported that an abnormal (positive or indeterminate)
WA exercise test was a better predictor of all-cause
ortality than was a QRSd 120 ms among 177 “MADIT
I-like” patients in long-term follow-up. Similarly, Zabel et
l. (2) found that a positive TWA test was a long-term
redictor of a combined end point of cardiac death or major
rrhythmic events (arrhythmogenic syncope or appropriate
hock delivery in patients with ICDs) among patients with
CM.
Numerous papers testified to the seemingly inexhaustible
otential of the venerable 12-lead surface electrocardiogram
ECG). In a study of 164 patients with ECG hallmarks of
he Brugada syndrome, Nava et al. (3) found that sudden
eath or ventricular fibrillation during long-term follow-up
as independently predicted by the degree of ST-segment
levation in lead VI, the amplitude of the S-wave in lead I,
nd the presence of an S-wave in lead II. A clinical study by
anders et al. (4) was one of two that yielded ECG markers
or differentiating various forms of atrial flutter. Those, for
nstance, that helped distinguish left atrial flutter included
n isoelectric P-wave in lead I/aVL, no transition from
egative to positive or vice versa in the chest leads, and a low
Abbreviations and Acronyms
AF  atrial fibrillation
AV  atrioventricular
Cai  intracellular calcium
CRT  cardiac resynchronization therapy
DCM  dilated cardiomyopathy
ECG  electrocardiographic
HCM  hypertrophic cardiomyopathy
ICD  implantable cardioverter-defibrillator
LV  left ventricular
LVEF  left ventricular ejection fraction
MI  myocardial infarction
NYHA  New York Heart Association
PV  pulmonary vein
QRSd  QRS duration
RF  radiofrequency
RV  right ventricular
TWA  T-wave alternans
VT  ventricular tachycardia-wave amplitude in all leads except VI. aEVICES FOR TACHYCARDIAS AND BRADYCARDIAS
here were important presentations on the use of the ICD
or patients at risk of arrhythmic death but lacking tradi-
ional indications for implantation. Among previously re-
orted randomized studies of such patients, the MADIT II
ound a statistically significant all-cause mortality advantage
n supplementing conventional medical therapy with an
CD for patients with an LVEF30% and a history of MI.
imilarly, the Sudden Cardiac Death in Heart Failure Trial
SCD-HeFT) found that the ICD but not amiodarone
herapy significantly reduces all cause five-year mortality in
atients with ischemic or nonischemic New York Heart
ssociation (NYHA) functional class II or III heart failure
nd an LVEF35%. At the meeting, Jeanne E. Poole, MD
University of Washington, Seattle, Washington), reported
hat a new analysis of SCD-HeFT results could not identify
ny ECG markers for selecting patients most likely to
enefit from ICD therapy. A QRSd 120 ms did not
redict mortality benefit in this new, focused, SCD-HeFT
nalysis.
N. A. Mark Estes, MD (New England Medical Center,
oston, Massachusetts), reported on the Defibrillators in
on-Ischemic-cardiomyopathy Treatment Evaluation
DEFINITE) trial, which compared medical therapy alone
ith medical therapy plus an ICD for patients with non-
schemic DCM and an LVEF 35%. The ICD was
ssociated with: 1) a reduction in all-cause mortality that
as statistically non-significant overall but significant for
atients in NYHA functional class III (as opposed to I or II)
eart failure, and 2) a significant reduction in the five-year
ate of sudden cardiac death. Because of optimized medical
herapy, the annual risk of death in the control group was
nly 7%.
In the Defibrillators in Acute Myocardial Infarction Trial
DINAMIT), patients with an LVEF 35% and reduced
eart rate variability were randomized to receive or not
eceive an ICD 6 to 40 days after an acute MI. A previously
eported DINAMIT analysis had found that the ICD
ignificantly reduced arrhythmic but not all-cause death
wing to an increase in nonarrhythmic death. A new
INAMIT analysis, reported by Paul Dorian, MD (Uni-
ersity of Toronto, Toronto, Ontario, Canada), found that:
) the increase in nonarrhythmic death among ICD recip-
ents was confined to those receiving shocks, and 2) the
ajority of the nonarrhythmic deaths were cardiovascular.
ne potential explanation for the superior ICD results with
ost-MI patients in MADIT II is that the average patient
as enrolled six years after the acute MI, allowing for
reater infarct stability. The DINAMIT study indicates
hat patients with a heavy ischemic burden early after acute
I are questionable candidates for the ICD.
Presentations on antibradycardia devices highlighted ef-
orts to achieve safe and effective function within magnetic
esonance scanners; the emergence of remote monitoring
nd automaticity (e.g., automatic atrial capture); and
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Highlights of Heart Rhythm 2004 October 19, 2004:1550–6rogress in developing biologic pacemakers (e.g., by genet-
cally engineered conversion of human ventricular myocytes
o pacemaker cells with spontaneous and rhythmic action
otentials). An assumption that suppression of premature
trial contractions will prevent AF has encouraged program-
ing of pacemakers to high rates. One presentation de-
cribed a relevant randomized comparison of two pacing
lgorithms: one providing high-rate antibradycardia pacing
nd preventive antitachycardia pacing, with the other em-
loying antitachycardia pacing algorithms alone without
igh-rate background atrial pacing. The results showed
ewer episodes of atrial arrhythmias without the use of
igh-rate back-up atrial pacing.
Daoud et al. (5) reported a new analysis from the Post AV
ode Ablation Evaluation (PAVE) study, a randomized
omparison of biventricular and right ventricular (RV)
pical pacing in patients with chronic AF after atrioventric-
lar (AV) node ablation to control rapid ventricular rates.
n earlier PAVE analysis had linked biventricular pacing to
ignificantly greater improvement in achieved distance on a
ix-minute walk test and in scores on a validated global
ealth inventory. The new analysis found that the advantage
n both assessments was confined to patients with an LVEF
35% before AV node ablation. A follow-up of only six
onths precluded exploration of whether long-term RV
pical pacing might impair LV function. However, given
revious favorable evidence on the long-term results of such
acing after AV node ablation, the investigators judged it
cceptable in patients with baseline preservation of LV
unction.
ARDIAC RESYNCHRONIZATION/
ENTRICULAR FUNCTION
estifying to the explosion of interest in biventricular
acing, one-third to one-half of the device presentations
oncerned resynchronization therapy, an approximate five-
old increase over the past five years. Biventricular pacing
urrently is approved only for NYHA functional class III
nd IV heart failure patients with an LVEF 35% and a
RSd 120 ms. Many presentations at the meeting fo-
used on CRT for subgroups of patients who were not
ell-represented in previous clinical trials. For example,
oes baseline AF predict lesser mortality benefit? Verdicts
onflicted, one being that it does for heart failure patients
ho are in NYHA functional class III but not IV (6).
ead-placement failure was found to be more common
mong women than men, but, in its absence, gender did not
redict mortality benefit (7). Patients with right bundle-
ranch block did as well as the majority with left bundle-
ranch block, but patients with non-specific intraventricular
onduction delay did not (8). Virtually all the subpopulation
ndings, however, came from studies with small cohorts,
etrospective designs, or other limitations that precluded
efinitive analysis (9).
There was preliminary support for extending CRT to ride-QRS patients with mild heart failure. In the previously
eported Multicenter InSync Randomized Clinical Evalua-
ion (MIRACLE) ICD II trial, randomization of such
atients to CRT versus no CRT yielded better six-month
utcomes in terms of LVEF and a combined clinical end
oint of death, hospitalization, and a patient self-assessment
core. Similarly, in a comparison of NYHA functional class
I patients and class III and IV counterparts for the
hree-month effects of CRT, no differences in six-min walk
est performance were observed.
In a boost to the controversial concept of CRT by
ingle-site pacing, a randomized comparison of CRT by
iventricular or isolated LV pacing for standard candidates
ndicated that both yield similar long-term results in terms
f LV function, mortality, and complications (10).
Heart failure aside, data were presented on the potential
dverse effects of standard RV apical anti-bradycardia pac-
ng. The latter is a known cause of mechanical interventric-
lar dyssynchrony, a likely explanation for its association
ith deterioration of LV function. Further doubts about
ingle-site RV pacing were raised by a crossover comparison
f two six-month DDD regimens for patients with sinus
radycardia, preserved AV conduction, and a narrow QRS.
elative to pacing that capitalized on spontaneous AV
onduction, pacing that mandated RV apical stimulation
as associated with impaired LV contraction and a reduced
uality of life (11).
ATHETER ABLATION
esearch into radiofrequency (RF) catheter ablation for AF
nd ventricular tachycardia (VT) was highlighted at the
eeting. For AF, an RF catheter is passed into the left
trium by transseptal puncture for ablation around the
ulmonary veins (PVs), which are often the sources of
riggering discharges. Debate continues as to the optimal
pproach and the importance of complete electrical isolation
f the PVs. Of two rival methods, one involves segmental
issue ablation near the PV ostium under guidance from a
ecording catheter seeking to abolish PV potentials. The
econd method is an anatomically guided circumferential
pproach that widely encircles the PV ostium. Lemola et al.
12) reported that the latter approach usually fails to achieve
lectrical isolation of all PVs, but persistent PV conduction
oes not predict recurrence of AF. Another study random-
zed 100 patients to circumferential or segmental ablation
or drug-refractory AF. As described at a late-breaking
linical trial session by Claus Schmitt, MD (German Heart
enter, Munich, Germany), Holter monitoring at six
onths revealed a higher rate of freedom from AF and/or
trial flutter (considered a proarrhythmic treatment effect)
n the segmental ablation group (71% vs. 47%; p  0.45),
hallenging previous evidence of greater efficacy for circum-
erential ablation. Interestingly, the very intensive monitor-
ng during follow-up convincingly demonstrated that recur-
ent arrhythmias are often asymptomatic, illustrating the
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October 19, 2004:1550–6 Highlights of Heart Rhythm 2004imitations of using patient-reported symptoms to assess
fficacy.
Schreieck et al. (13) explored RF ablation to prevent VT
ecurrences for patients receiving ICDs. Patients receiving
CDs for sustained monomorphic VT caused by previous
I were randomized to undergo or not undergo ablation.
blation did not significantly reduce the proportion of
atients receiving ICD shocks for VT during follow-up but
id reduce the number of VT episodes. Ventricular tachy-
ardia recurrences after ablation occurred because of an
nducible VT that had been judged “non-clinical” and not
argeted by ablation, or to a new VT from a region that had
ot been ablated, or to recurrence of the initial VT attrib-
ted to healing of the initially effective RF, arguing for more
xtensive ablation procedures for this type of VT (13).
Many VTs are hemodynamically unstable, such that
recise mapping during VT is not possible. During stable
inus rhythm, however, the infarct substrate that causes
any VTs can potentially be identified from maps that
how the amplitude of the electrical signal. This substrate
rea is usually very large such that complete catheter
blation is not practical. Two reports explored approaches to
uiding ablation of unmappable forms of VT. In post-MI
atients, Wilber et al. (14) found that pace-mapping during
inus rhythm identified potential VT exit regions in the
nfarct border where lines of RF ablation often achieved
blation of unstable VT. In an alternative approach, also
uring stable sinus rhythm, Nakagawa et al. (15) assessed
he electrograms recorded in the infarct region for the
resence of isolated late potentials that can represent islands
f surviving myocardium that support reentry. They ob-
erved that elimination of all detected isolated late potentials
n a low-voltage area by RF ablation usually abolished
nmappable VTs. The presence of a relatively small low-
oltage area was a predictor of VT recurrence during
ollow-up, which occurred in about 25% of patients. These
eports on RF ablation for post-infarct VT collectively
upport its use to reduce VT episodes as adjunctive therapy,
ut not as an alternative to the ICD (15).
LINICAL ELECTROPHYSIOLOGY
ND PHARMACOLOGY
n clinical electrophysiology, arrhythmia mechanisms and
ew antiarrhythmic medications were major topics of inter-
st. The traditional view of the mechanism underlying AF is
hat the arrhythmia is initiated by rapidly discharging
riggers originating predominately in the PVs, and is main-
ained by atrial tissue (substrate). Recent observations chal-
enge this notion. Dr. Michel Haissaguerre presented evi-
ence that as the PVs were isolated, the cycle length
easured at sites removed from the veins in the left atrium
along the coronary sinus) prolonged. When all PVs were
solated, AF terminated and was not inducible in 56% of
atients. This suggests that the PV foci not only initiate but
erpetuate AF. Similarly, in a reported 30-year follow-up of gayo Clinic (Rochester, Minnesota) patients with lone
aroxysmal AF, only 25% developed chronic AF in long-
erm follow-up (16). This raises questions about whether
AF begets AF” in this population, as is commonly believed,
r whether AF is dependent on ongoing trigger discharge
or its maintenance. In further support of the latter concept,
ewer than 5% of patients with ectopy or paroxysmal
upraventricular tachycardia at initial diagnosis developed
hronic AF.
A report on the Prevention of Syncope Trial by Robert
heldon, MD (University of Calgary, Alberta, Canada),
ddressed the issue of whether beta-blockers are effective in
reventing vasovagal syncope. As described, 208 patients
ith historical and tilt-test documentation of vasovagal
yncope were randomized to receive metoprolol or placebo.
he risk of syncope recurrence was not significantly reduced
n the overall metoprolol group but was in a subgroup
efined by an age 42 years. This finding prompted the
nvestigators to recommend metoprolol for this age group,
ut they also cautioned that the results did not necessarily
pply to beta-blockers as a class. Metoprolol was not
ssociated with an excess of adverse events. Challenging
revious evidence, benefit from metoprolol was not pre-
icted by a need for an isoproterenol infusion to produce a
ositive baseline tilt test.
There was much interest in the novel antiarrhythmic drug
ronedarone, a deiodinated congener of amiodarone that
ay offer antiarrhythmic effects of the latter without its full
ange of toxicity. Approximately 20% to 30% of patients
ith ICDs require concomitant antiarrhythmic medications
o prevent frequent shocks. Although amiodarone may
educe ICD shock frequency, it is known to raise defibril-
ation and pacing thresholds. In a pilot study reported by
eter R. Kowey, MD (MainLine Heart Health Center,
ynnewood, Pennsylvania), 76 ICD recipients with coro-
ary artery disease and/or DCM and an LV EF40% were
andomized to any of the four following treatments: placebo
r dronedarone at doses of 600, 800, and 1,000 mg twice
aily.
The results indicated that dronedarone does not increase
he defibrillation threshold. Relative to placebo, no dose of
ronedarone significantly increased the proportion of pa-
ients with a defibrillation safety margin of 10 J, the
rimary end point. This undesired safety margin was ob-
erved in only two patients in the entire population, both in
he 1,600 mg/day group. Dronedarone was associated with
lower rate of appropriate ICD discharges (a secondary end
oint) that constituted a statistical trend over an initial 30
ays and became significant in long-term follow-up. Drone-
arone had no significant effect on pacing thresholds. The
lasma concentrations of dronedarone and its dibutyl me-
abolite were expectedly dose-related, and increased over the
nitial 30 days, suggesting an accumulation of the drug
uring chronic dosing.
The most common adverse events with dronedarone wereastrointestinal. The 2,000-mg/day dose was associated
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Highlights of Heart Rhythm 2004 October 19, 2004:1550–6ith incidences of adverse events and early treatment
iscontinuations that were judged unacceptable. Lower
oses were generally well-tolerated. Only one death in the
rial was judged related (possibly) to dronedarone. No cases
f torsade de pointes or ventricular proarrhythmia were
eported. These promising preliminary results await confir-
ation from larger and longer-term trials.
ONGENITAL AND PEDIATRIC HEART DISEASE
he presentations on pediatric and congenital heart disease
t this year’s meeting differed from those of recent prede-
essors by a shift in emphasis away from ablation for
upraventricular arrhythmias and towards CRT and topics
elated to sudden cardiac death.
In North America, hypertrophic cardiomyopathy (HCM)
s the most commonly identified underlying cause of sudden
ardiac death in young athletes. Recognition that HCM is
aused by mutations of up to 10 genes that encode proteins
f the myocardial sarcomere has fueled efforts to develop a
eliable genetic test for the disease. A report by Ackerman et
l. (17) described a promising candidate test that screens for
variety of these mutations. The yield of the test for
atients with known HCM was highest for those with any
f the following traits: receiving a diagnosis of HCM at an
ge 25 years, a history of cardiac arrest, a family history of
CM, and a very thick left ventricle (17).
Coexistent HCM and Wolff-Parkinson-White syndrome
s a manifestation of a glycogen storage disease that has been
raced to a defect in the PRKAG2 gene in familial but not
poradic cases. However, Collins et al. (18) reported that a
utation of this gene was found in one of a few pediatric
atients who had sporadic forms of the combined disease
nd had presented with a diversity of electrophysiologic
isturbances (including supraventricular tachycardia and
entricular fibrillation). A very common trait in this group
as the existence of multiple accessory pathways (five in the
ase of the patient with the PRKAG2 gene mutation).
reatments for the group included RF ablation of the
athways (successful in most of the cases) and implantation
f an ICD (18).
In a didactic presentation, Michael A. Gatzoulis, MD
Royal Brompton Hospital, London, UK), discussed a
rolonged QRSd (usually 170 ms) as a robust predictor of
ife-threatening arrhythmias in pediatric patients with right
undle-branch block after surgery for congenital heart
isease. Rapid increase of the QRSd appears to be especially
minous. Recent data, he said, indicate that the two
lectrophysiologic markers improve after surgery for pulmo-
ary valve insufficiency or other causes of underlying hemo-
ynamic disturbances.
Robert M. Campbell, MD (Sibley Heart Center, Atlanta,
eorgia) and Robert M. Gow, MD (The Children’s Hos-
ital of Eastern Ontario, Ottawa, Canada), served as pro-
agonist and antagonist, respectively, in a structured debate
n whether ECG and echocardiographic screening should pe a routine prerequisite for participation in school-age
rganized athletics. They agreed that both techniques pro-
uce high false-positive and false-negative rates. The limi-
ations of these and other methods of identifying sudden
ardiac death risk in young athletes have contributed to a
rend to place automatic external defibrillators in public
chools and other school-age sport sites. In a didactic
resentation, Stuart Berger, MD (Medical College of Wis-
onsin, Milwaukee, Wisconsin), described a systematic
ffort in Wisconsin to protect young athletes by combining
utomatic external defibrillator placement with ancillary
ublic education and training of operators. The annual
udden death rate among young athletes in Wisconsin is 0.5
o 2.0 per 100,000, consistent with the national rate.
Clinical data on CRT come largely from its use in adults
ithout congenital heart disease. Alexander et al. (19)
eported that the traditional adult-derived indications for
RT were present in only approximately 10% of a cohort of
53 pediatric patients (mean age 5.4 years) with LV
ysfunction. A combination of left bundle-branch block and
QRSd 150 ms was uncommon and remained so when
he patients were subgrouped for the presence of congenital
eart disease or ostensibly normal cardiac structure. More-
ver, many of the CRT-eligible patients would have re-
uired epicardial leads for CRT because of body weights
10 kg or single-ventricle anatomy. The same study also
ound that CRT was not commonly indicated in a different
ohort of pediatric patients who had an indication for
entricular pacing in the presence or absence of LV dys-
unction. In this group (n 160), the paced QRS tended to
e narrow, particularly in patients 10 years of age (19).
ubin et al. (20) reported on the use of CRT at 13 centers
or 52 patients with structural congenital heart disease,
ongenital heart block, or DCM. The indications for CRT
nd the type and placement of the lead system for biven-
ricular pacing were not standardized. Therapy was accom-
anied by a mean QRSd reduction of 40 ms, an increase in
ean LVEF from 28% to 39%, and a general improvement
n NYHA functional class. Approximately one-half the
atients required placement of epicardial lead systems.
on-response to CRT did not seem to correlate with type
f underlying heart disease (20). In a didactic session, Frank
. Zimmerman, MD (University of Chicago Children’s
ospital, Chicago, Illinois), showed how three-dimensional
chocardiography in patients with single-ventricle anatomy
ould help identify suitable locations for multisite pacing
nd, thus, improve global function.
Two emerging indications for CRT among patients with
ediatric or congenital heart disease are right bundle-branch
lock resulting from RV surgery and a history of RV apical
acing from childhood for congenital heart block. In a
omparison of adults with the latter trait and healthy
olunteers, Thambo et al. (21) found that long-term asyn-
hronous electromechanical activation by RV apical pacing
roduces asymmetrical hypertrophy, LV dilation, and im-
airment of LV function. Such deterioration might be
p
s
C
c
n
b
B
T
i
i
c
F
m
h
v
t
m
t
t
m
m
fi
s
(
m
s
c
e
i
a
a
l
h
a
a
r
s
t
E
c
w
s
r
h
a
c
b
l
s
t
h
h
e
H
N
o
I
t
o
t
t
R
U
G
R
1
1
1
1
1
1
1
1555JACC Vol. 44, No. 8, 2004 Curtis et al.
October 19, 2004:1550–6 Highlights of Heart Rhythm 2004revented or halted by substituting biventricular for single-
ite pacing, said Patricio A. Frias, MD (Sibley Heart
enter, Atlanta, Georgia), in a didactic session. Frias and
olleagues have found the biventricular approach hemody-
amically superior in an animal model of congenital heart
lock.
ASIC/TRANSLATIONAL SCIENCE
he San Francisco meeting bore witness to the fact that an
mportant current theme in basic cardiac electrophysiology
s the relationship between the dynamics of intracellular
alcium (Cai) and the mechanisms of cardiac arrhythmias.
or example, Rajawat et al. (22) developed a transgenic
ouse model of Andersen syndrome (a rare inherited
uman disorder characterized by periodic paralysis and
entricular arrhythmias) by overexpressing a mutant gene
hat encodes the slow rectifying K channel (Kir2.1). The
ouse developed bidirectional VT, suggesting abnormali-
ies of Cai dynamics (22). Tian et al. (23) developed a
ransgenic mouse with selective cardiac expression of a
utated sodium channel gene (SCN5A, N1325S). The
odel was characterized by spontaneous VT/ventricular
brillation (preceded by single or multiple ventricular extra-
ystoles), up-regulation of the cardiac ryanodine receptor
RyR2) (which mediates calcium release from the sarcoplas-
ic reticulum in cardiac myocytes, thereby contributing to
ystolic function), and down-regulation of the Na-Ca ex-
hanger. The authors concluded that the arrhythmogenic
ffects of a gain-of-function mutation contribute to Cai
mbalance, which in turn triggers lethal arrhythmias. In
ddition, the pattern of observed arrhythmias suggested that
bnormal Cai dynamics may contribute to the triggering of
ethal arrhythmias associated with the long QT syndrome in
umans (23). The studies by Rajawat et al. (22) and Tian et
l. (23) are particularly interesting because the mutations
ffect the K and Na channels, but the arrhythmogenesis is
elated to abnormal Cai dynamics.
Miyoshi et al. (24) conducted a computer simulation
tudy of the Brugada syndrome. Their results showed that
he dispersion of ICaL density in the RV can simulate the
CG changes associated with the syndrome. The authors
oncluded that it is possible to develop Brugada syndrome
ithout an SCN5A mutation, which is a known cause of the
yndrome but is associated with abnormalities of the Na
ather than Ca channel (24). This third study further
ighlights the possible importance of calcium dynamics in
rrhythmogenesis.
Additional information on the role of Cai dynamics in
ardiac arrhythmogenesis was presented at didactic sessions
y invited speakers. One noted that a rapid heart rate can
ead to Cai accumulation, which might in turn result in
pontaneous (voltage-independent) calcium release and
rigger ventricular arrhythmias. Others described significant
eterogeneity in the transmural distribution of calcium-andling proteins. These changes may contribute to the
lectrical heterogeneity of the ventricles.
EART RHYTHM 2005
ext year’s meeting will be held in New Orleans, Louisiana,
n May 4 to 7, 2005. It will be interesting to see if CRT, the
CD, and other topics so dominant this year remain so in
he next. Change occurs rapidly in cardiac electrophysiol-
gy. The challenge of understanding and taming the elec-
rical components of cardiac disease is exceptional, but so is
he pace at which it is being met.
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